EN

Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review

30/03/2009

Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review
Patient Preference and Adherence 2008: 2, 357–367
The worldwide introduction of the first, unique patch for hormonal contraception (ethinyl estradiol/norelgestromin, EE/NGMN patch) was widely recognized as a significant event in the development of drug delivery systems. This innovation offers a number of advantages over the oral route, and extensive clinical trials have proved its safety, efficacy, effectiveness, and tolerability.
The weekly administration and ease of use/simplicity of the EE/NGMN patch contribute to its acceptability, and help to resolve the two main problems of non-adherence, namely early discontinuation and inconsistent use.
The patch offers additional benefi ts to adolescents (improvement of dysmenorrhea and acne), adults (improvement in emotional and physical well-being, premenstrual syndrome, and menstrual irregularities), and perimenopausal women (correction of hormonal imbalance, modulation of premenopausal symptoms), thus providing high satisfaction rates (in nearly 90% of users).
Since its introduction, the transdermal contraceptive patch has proved to be a useful choice for women who seek a convenient formulation which is easy to use, with additional, non-contraceptive tailored benefits for all the ages.

Allegati disponibili:Full text dell'articolo

Iscriviti alla newsletter